ChiCTR2600123634 版本V1.0 版本创建时间2026/04/28 15:22:28 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123634 

最近更新日期:

Date of Last Refreshed on:

2026-04-28 15:22:01 

注册时间:

Date of Registration:

2026-04-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

右美托咪定鼻喷雾剂在儿童术前镇静效果以及安全性研究评估

Public title:

Evaluation of the Efficacy and Safety of Dexmedetomidine Nasal Spray for Preoperative Sedation in Children

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右美托咪定鼻喷雾剂在儿童术前镇静效果以及安全性研究评估

Scientific title:

Evaluation of the Efficacy and Safety of Dexmedetomidine Nasal Spray for Preoperative Sedation in Children

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈忠华 

研究负责人:

陈忠华 

Applicant:

Chen Zhonghua 

Study leader:

Chen Zhonghua 

申请注册联系人电话:

Applicant telephone:

+86 136 2575 1526

研究负责人电话:

Study leader's telephone:

+86 136 2575 1526

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

chenbeijing116@163.com

研究负责人电子邮件:

Study leader's E-mail:

chenbeijing116@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省绍兴市越城区中心北路 568 号

研究负责人通讯地址:

浙江省绍兴市越城区中心北路 568 号

Applicant address:

No. 568, Central North Road, Yuecheng District, Shaoxing City, Zhejiang Province

Study leader's address:

No. 568, Central North Road, Yuecheng District, Shaoxing City, Zhejiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

绍兴市人民医院

Applicant's institution:

Shaoxing People's Hospital

研究负责人所在单位:

绍兴市人民医院

Affiliation of the Leader:

Shaoxing People's Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-研 039-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

绍兴市人民医院学术伦理委员会

Name of the ethic committee:

Shaoxing People's Hospital Academic Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-10 00:00:00

伦理委员会联系人:

鲁葆春

Contact Name of the ethic committee:

Lu Baochun

伦理委员会联系地址:

浙江省绍兴市越城区中心北路 568 号

Contact Address of the ethic committee:

No. 568, Central North Road, Yuecheng District, Shaoxing City, Zhejiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 575 8855 9250

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

绍兴市人民医院

Primary sponsor:

Shaoxing People's Hospital

研究实施负责(组长)单位地址:

浙江省绍兴市越城区中心北路 568 号

Primary sponsor's address:

No. 568, Central North Road, Yuecheng District, Shaoxing City, Zhejiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

绍兴市人民医院

具体地址:

浙江省绍兴市越城区中心北路 568 号

Institution
hospital:

Shaoxing People's Hospital

Address:

No. 568, Central North Road, Yuecheng District, Shaoxing City, Zhejiang Province

经费或物资来源:

上海恒瑞医药有限公司

Source(s) of funding:

Shanghai Hengrui Pharmaceutical Co., Ltd.

Target disease:

Surgery for Pediatric Patients

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在观察右美托咪定鼻喷雾剂在儿童手术中的疗效及安全性,为其在儿童手术麻醉中的临床应用提供更充分的依据。具体包括评估右美托咪定鼻喷雾剂对患儿术前焦虑、术中镇静深度、术后疼痛程度的影响,以及观察其在应用过程中是否出现不良反应,如呼吸抑制、低血压、心动过缓等,从而确定其在儿童手术中应用的有效性和安全性。  

Objectives of Study:

This study aims to observe the efficacy and safety of dexmedetomidine nasal spray in pediatric surgery, to provide a more substantial basis for its clinical application in pediatric anesthesia. Specifically, it includes evaluating the effects of dexmedetomidine nasal spray on preoperative anxiety, intraoperative sedation depth, and postoperative pain level in children, as well as observing any adverse reactions during its application, such as respiratory depression, hypotension, bradycardia, etc., thereby determining its effectiveness and safety in pediatric surgical procedures.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄在 2 - 6 岁之间,拟在全身麻醉下接受各类手术的患儿,如小儿普外科手术(如腹股沟疝修补术、阑尾切除术等)、小儿泌尿外科手术(如包皮环切术、隐睾下降固定术等)、小儿耳鼻喉科手术(如腺样体切除术、扁桃体切除术等); 2.美国麻醉医师协会(ASA)分级为 Ⅰ - Ⅱ 级 ; 3.体重指数10.7~28 kg/m^2; 4.患儿家属签署知情同意书。

Inclusion criteria

1. Children aged between 2 and 6 years old who are scheduled to undergo various surgeries under general anesthesia, such as pediatric general surgery (e.g., inguinal hernia repair, appendectomy, etc.), pediatric urology surgery (e.g., circumcision, cryptorchidism descent fixation, etc.), and pediatric otolaryngology surgery (e.g., adenoidectomy, tonsillectomy, etc.); 2. American Society of Anesthesiologists (ASA) classification of grades I - II; 3. Body mass index ranging from 10.7 to 28 kg/m^2; 4. The parents of the children sign the informed consent form.

排除标准:

1.存在严重的心肺功能障碍、肝肾功能不全、神经系统疾病等可能影响研究结果的基础疾病; 2.对右美托咪定或其他相关药物过敏; 3.近期(术前 1 周内)有上呼吸道感染史; 4.鼻腔解剖结构异常或存在鼻腔疾病(如鼻中隔偏曲、鼻窦炎等)影响药物吸收; 5.有药物滥用史或精神疾病史。

Exclusion criteria:

1. There are underlying diseases that may affect the research results, such as severe cardiopulmonary dysfunction, liver and kidney dysfunction, and neurological disorders; 2. Allergic to dexmedetomidine or other related drugs; 3. Had a history of upper respiratory tract infection within the recent 1 week before the surgery; 4. Abnormal nasal anatomy or nasal diseases (such as deviation of the nasal septum, sinusitis, etc.) that affect drug absorption; 5. History of drug abuse or mental illness.

研究实施时间:

Study execute time:

From 2026-04-20 00:00:00 To 2028-04-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-28 00:00:00 To 2028-04-20 00:00:00  

干预措施:

Interventions:

组别:

右美托咪定鼻喷雾剂组(试验组)

样本量:

400

Group:

Dexmedetomidine Nasal Spray Group (Experimental group)

Sample size:

干预措施:

右美托咪定鼻喷雾剂。根据体重经鼻腔给药(10.7kg<=体重<19.4kg给予1喷,19.4kg<=体重<=28kg给予2喷),总给药剂量为25μg/喷或50μg(取决于喷数)。具体操作遵循药品说明书(如首次预喷、保持鼻腔清洁、头部位置等)。

干预措施代码:

Intervention:

Dexmedetomidine nasal spray. Intranasal administration was based on body weight (one puff for 10.7kg<= body weight <19.4kg and two sprays for 19.4kg<= body weight <=28kg), with a total dose of 25μg/ puff or 50μg (depending on the number of sprays). The specific operation followed the instructions of the drug (such as the first pre-spray, keep the nose clean, head position, etc.).

Intervention code:

组别:

生理盐水组(对照组)

样本量:

400

Group:

Normal Saline Group (Control group)

Sample size:

干预措施:

外观相同的生理盐水鼻喷雾剂。给药方式、时间、喷数与试验组完全相同。

干预措施代码:

Intervention:

Saline nasal spray identical in appearance. The administration method, timing, and number of sprays are identical to those in the experimental group.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China 

Province:

Zhejiang  

City:

 

单位(医院):

绍兴市人民医院 

单位级别:

三甲 

Institution
hospital:

Shaoxing People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术前改良的Ramsay镇静评分

指标类型:

主要指标

Outcome:

preoperative modified Ramsay Sedation Scale (RSS) score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗依从性量表(Frankl量表)评分

指标类型:

次要指标

Outcome:

Frankl Behavior Rating Scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

父母分离焦虑量表(PSAS)评分

指标类型:

次要指标

Outcome:

Parental Separation Anxiety Scale (PSAS) score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良耶鲁术前焦虑量表评分

指标类型:

次要指标

Outcome:

modified Yale Preoperative Anxiety Scale (m-YPAS) score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

面罩接受度

指标类型:

次要指标

Outcome:

assessment of mask acceptance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

诱导合作量表(ICC)评分

指标类型:

次要指标

Outcome:

Induction Compliance Checklist (ICC) score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围术期不良反应

指标类型:

次要指标

Outcome:

perioperative adverse reactions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围术期用药情况

指标类型:

次要指标

Outcome:

perioperative medication profile

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围术期生命体征

指标类型:

次要指标

Outcome:

perioperative vital signs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

外科医生操作满意度评分

指标类型:

次要指标

Outcome:

Surgeon's Satisfaction Score with the Procedure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

苏醒时间(停药至患儿按指令睁眼的时间)

指标类型:

次要指标

Outcome:

Time to Emergence (from discontinuation of the drug to the child opening eyes on command)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PACU停留时间

指标类型:

次要指标

Outcome:

Length of Stay in the PACU

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

拔管时间

指标类型:

次要指标

Outcome:

Time to Extubation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

躁动评分(PAED)

指标类型:

次要指标

Outcome:

PAED Scale (Pediatric Anesthesia Emergence Delirium Scale)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分 (FLACC)

指标类型:

次要指标

Outcome:

FLACC Scale (Face, Legs, Activity, Cry, Consolability Scale)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 2 years
最大 Max age 6 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用系统抽样进行随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random allocation was performed using systematic sampling.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲,对研究参与者和研究者设盲

Blinding:

Double-blind, with both the research participants and the researchers being blinded.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-28 15:22:01